Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation

Joost J C Verhoeff; Lukas J A Stalpers; Cornelis J F Van Noorden; Dirk Troost; Marja D Ramkema; Chris van Bree; Ji-Ying Song; Mila Donker; Martha Chekenya; W Peter Vandertop; Dick J Richel; Wouter R van Furth

doi:10.1016/j.canlet.2009.04.038

Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation

Joost J C Verhoeff, Lukas J A Stalpers, Cornelis J F Van Noorden, Dirk Troost, Marja D Ramkema, Chris van Bree, Ji-Ying Song, Mila Donker, Martha Chekenya, W Peter Vandertop, Dick J Richel, Wouter R van Furth

Department of Radiotherapy

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The combination of irradiation with angiogenic inhibition is increasingly being investigated for treatment of glioblastoma multiforme (GBM). We investigated whether vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor DC101 affects morbidity and tumor growth in irradiated and non-irradiated intracerebral GBM-bearing mice, controlled with sham treatments. End-points were toxicity, morbidity and histology. Irradiation either or not combined, reduced tumor size strongly, whereas DC101 mono-treatment reduced tumor size by 64%. Irradiation delayed morbidity from 5.8 weeks in sham-treated mice to 10.3 weeks. Morbidity after combined treatment occurred after 5.9 weeks. Treatment with angiogenesis inhibitor DC101 delays tumor growth but it induces morbidity, by itself or combined with irradiation.

Original language	English
Pages (from-to)	39-45
Number of pages	7
Journal	Cancer Letters
Volume	285
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2009.04.038
Publication status	Published - 18 Nov 2009

Keywords

Angiogenesis Inhibitors
Animals
Antibodies, Monoclonal
Brachytherapy
Brain Neoplasms
Cell Line, Tumor
Cell Proliferation
Chemotherapy, Adjuvant
Cranial Irradiation
Female
Glioblastoma
Humans
Mice
Mice, Nude
Necrosis
Neovascularization, Pathologic
Radiotherapy, Adjuvant
Time Factors
Vascular Endothelial Growth Factor Receptor-2
Journal Article

Access to Document

10.1016/j.canlet.2009.04.038

Cite this

Verhoeff, J. J. C., Stalpers, L. J. A., Van Noorden, C. J. F., Troost, D., Ramkema, M. D., van Bree, C., Song, J.-Y., Donker, M., Chekenya, M., Vandertop, W. P., Richel, D. J., & van Furth, W. R. (2009). Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation. Cancer Letters, 285(1), 39-45. https://doi.org/10.1016/j.canlet.2009.04.038

@article{7d16a67cca164eb5b82d31c8611ad6fc,

title = "Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation",

abstract = "The combination of irradiation with angiogenic inhibition is increasingly being investigated for treatment of glioblastoma multiforme (GBM). We investigated whether vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor DC101 affects morbidity and tumor growth in irradiated and non-irradiated intracerebral GBM-bearing mice, controlled with sham treatments. End-points were toxicity, morbidity and histology. Irradiation either or not combined, reduced tumor size strongly, whereas DC101 mono-treatment reduced tumor size by 64%. Irradiation delayed morbidity from 5.8 weeks in sham-treated mice to 10.3 weeks. Morbidity after combined treatment occurred after 5.9 weeks. Treatment with angiogenesis inhibitor DC101 delays tumor growth but it induces morbidity, by itself or combined with irradiation.",

keywords = "Angiogenesis Inhibitors, Animals, Antibodies, Monoclonal, Brachytherapy, Brain Neoplasms, Cell Line, Tumor, Cell Proliferation, Chemotherapy, Adjuvant, Cranial Irradiation, Female, Glioblastoma, Humans, Mice, Mice, Nude, Necrosis, Neovascularization, Pathologic, Radiotherapy, Adjuvant, Time Factors, Vascular Endothelial Growth Factor Receptor-2, Journal Article",

author = "Verhoeff, {Joost J C} and Stalpers, {Lukas J A} and {Van Noorden}, {Cornelis J F} and Dirk Troost and Ramkema, {Marja D} and {van Bree}, Chris and Ji-Ying Song and Mila Donker and Martha Chekenya and Vandertop, {W Peter} and Richel, {Dick J} and {van Furth}, {Wouter R}",

year = "2009",

month = nov,

day = "18",

doi = "10.1016/j.canlet.2009.04.038",

language = "English",

volume = "285",

pages = "39--45",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

Verhoeff, JJC, Stalpers, LJA, Van Noorden, CJF, Troost, D, Ramkema, MD, van Bree, C, Song, J-Y, Donker, M, Chekenya, M, Vandertop, WP, Richel, DJ & van Furth, WR 2009, 'Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation', Cancer Letters, vol. 285, no. 1, pp. 39-45. https://doi.org/10.1016/j.canlet.2009.04.038

TY - JOUR

T1 - Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation

AU - Verhoeff, Joost J C

AU - Stalpers, Lukas J A

AU - Van Noorden, Cornelis J F

AU - Troost, Dirk

AU - Ramkema, Marja D

AU - van Bree, Chris

AU - Song, Ji-Ying

AU - Donker, Mila

AU - Chekenya, Martha

AU - Vandertop, W Peter

AU - Richel, Dick J

AU - van Furth, Wouter R

PY - 2009/11/18

Y1 - 2009/11/18

N2 - The combination of irradiation with angiogenic inhibition is increasingly being investigated for treatment of glioblastoma multiforme (GBM). We investigated whether vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor DC101 affects morbidity and tumor growth in irradiated and non-irradiated intracerebral GBM-bearing mice, controlled with sham treatments. End-points were toxicity, morbidity and histology. Irradiation either or not combined, reduced tumor size strongly, whereas DC101 mono-treatment reduced tumor size by 64%. Irradiation delayed morbidity from 5.8 weeks in sham-treated mice to 10.3 weeks. Morbidity after combined treatment occurred after 5.9 weeks. Treatment with angiogenesis inhibitor DC101 delays tumor growth but it induces morbidity, by itself or combined with irradiation.

AB - The combination of irradiation with angiogenic inhibition is increasingly being investigated for treatment of glioblastoma multiforme (GBM). We investigated whether vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor DC101 affects morbidity and tumor growth in irradiated and non-irradiated intracerebral GBM-bearing mice, controlled with sham treatments. End-points were toxicity, morbidity and histology. Irradiation either or not combined, reduced tumor size strongly, whereas DC101 mono-treatment reduced tumor size by 64%. Irradiation delayed morbidity from 5.8 weeks in sham-treated mice to 10.3 weeks. Morbidity after combined treatment occurred after 5.9 weeks. Treatment with angiogenesis inhibitor DC101 delays tumor growth but it induces morbidity, by itself or combined with irradiation.

KW - Angiogenesis Inhibitors

KW - Animals

KW - Antibodies, Monoclonal

KW - Brachytherapy

KW - Brain Neoplasms

KW - Cell Line, Tumor

KW - Cell Proliferation

KW - Chemotherapy, Adjuvant

KW - Cranial Irradiation

KW - Female

KW - Glioblastoma

KW - Humans

KW - Mice

KW - Mice, Nude

KW - Necrosis

KW - Neovascularization, Pathologic

KW - Radiotherapy, Adjuvant

KW - Time Factors

KW - Vascular Endothelial Growth Factor Receptor-2

KW - Journal Article

U2 - 10.1016/j.canlet.2009.04.038

DO - 10.1016/j.canlet.2009.04.038

M3 - Article

C2 - 19473756

SN - 0304-3835

VL - 285

SP - 39

EP - 45

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation

Abstract

Keywords

Access to Document

Fingerprint

Cite this